Topic: tumor mutational burden (TMB)
Merck’s immuno-oncology competitors have tried to win approvals using a new biomarker, so far fruitlessly. It looks like Merck itself might succeed.
Merck is throwing cold water on the idea that biomarker TMB can determine which lung cancer patients will best respond to its market-leading therapy.
AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.